Abstract: The present invention composition features pharmaceutically acceptable salts of psilocin and compositions thereof. The pharmaceutically acceptable salts of psilocin may be used to treat a disease or condition, such as a neurological injury, an inflammatory condition, chronic pain, or a psychological condition, in a subject in need thereof.
Type:
Grant
Filed:
March 30, 2022
Date of Patent:
June 20, 2023
Assignee:
Eleusis Therapeutics US, Inc.
Inventors:
David E. Nichols, Graham Johnson, Hooshang S. Zavareh, Claire Wombwell, Daniel Rixson, Peter Haddow, Carrie Sheard, Alexander Schwarz
Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
Type:
Grant
Filed:
July 9, 2021
Date of Patent:
June 6, 2023
Assignee:
Janssen Pharmaceutica NV
Inventors:
Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
Abstract: GHB drug delivery systems comprising a floating interpenetrating network (IPN) are provided. The pharmaceutical compositions contain at least one IPN forming system, at least GHB drug, and at least one gas generating agent, such that upon oral ingestion of the compositions, a floating IPN is formed in situ. These floating IPN provide extended release of the GHB drug entrapped therein for at least about 3 hours.
Type:
Grant
Filed:
December 18, 2018
Date of Patent:
June 6, 2023
Assignee:
TRIS PHARMA, INC
Inventors:
Paras Rameshlal Jain, Sachin Vasant Chaudhari
Abstract: The present disclosure provides a composition comprising crystalline forms A, B, and C of psilocin and psilocybin. Solvent screen, X-ray powder diffractogram, thermogravimetric mass spectroscopy, differential scanning calorimetry, 1H-NMR, dynamic vapor sorption, and UPLC data on each of the crystalline forms is presented, along with methods preparing each of the crystalline forms.
Abstract: The present invention relates to compounds of formula (I) as defined herein, which comprise a greater proportion of deuterium to protium than naturally found in hydrogen; and compositions, including pharmaceutical compositions, comprising these compounds and optionally analogous compounds of formula (I), which are not deuterium-enriched. These compounds and compositions are of use in therapy, in particular in the treatment of psychiatric or neurological disorders. Varying the amounts of the different compounds within the compositions of the invention allows tailoring of the compositions' therapeutic effects. A particularly efficient synthetic method which enables compounds of formula (I) and related compounds of formula (I?) is also provided.
Type:
Grant
Filed:
February 25, 2022
Date of Patent:
May 30, 2023
Assignee:
SMALL PHARMA LTD.
Inventors:
Peter Rands, Ellen James, Tiffanie Benway, Zelah Joel, Marie Layzell
Abstract: The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.
Type:
Grant
Filed:
December 18, 2020
Date of Patent:
May 30, 2023
Assignee:
Pfizer Inc.
Inventors:
Scott William Bagley, Agustin Casimiro-Garcia, Xiayun Cheng, Jennifer Elizabeth Davoren, Rajiah Aldrin Denny, Brian Stephen Gerstenberger, Frank Eldridge Lovering, Mihir Dineshkumar Parikh, Joseph Walter Strohbach, John Isidro Trujillo
Abstract: The invention relates to crystalline forms of a 3-substituted 1,2,4-oxadiazole compound, including an anhydrous crystalline form, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for pharmaceutical, veterinary, and agriculturally-relevant uses.
Abstract: An object is to provide a novel organic compound. Another object is to provide a novel light-emitting device. Another object is to provide a light-emitting device with favorable emission efficiency. Another object is to provide a light-emitting device with a favorable lifetime. Another object is to provide a light-emitting device with a low driving voltage. A dibenzo[c,g]carbazole derivative represented by the following general formula (G1) and a light-emitting device using it are provided. Note that at least one of R11 to R22 represents a substituent that has 14 to 60 carbon atoms in total and contains a condensed tricyclic to hexacyclic aromatic hydrocarbon skeleton, and the others independently represent any of hydrogen, an alkyl group having 1 to 6 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms, and a substituted or unsubstituted aryl group having 6 to 25 carbon atoms.
Abstract: One of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity. Another of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity and exhibits a protein degradation induction activity. The present invention provides a compound represented by formula (I) (the symbols in the formula are as defined in the present Description) and salts thereof.
Abstract: Provided herein are compounds of Formula (I), including methods of making the same. The disclosed compounds are succinate dehydrogenase inhibitors and can be useful in, e.g., inhibiting or preventing fungal growth.
Type:
Grant
Filed:
November 13, 2019
Date of Patent:
April 25, 2023
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Abstract: The invention provides a process for preparing heterocyclic fluoroalkenyl sulfones and their thioether and sulfoxide precursors of the formula: Cl—R—S(O)n—(CH2)2—CF?CF2 (Formula I?) wherein R is a heterocyclic five-membered aromatic ring and n is 0, 1 or 2, comprising a step of dehalogenation of a compound of the formula: Cl—R—S(O)n—(CH2)2—CFX1—CF2X2 (Intermediate B), wherein X1 and X2 are independently halogen atoms, to remove said X1 and X2 atoms. Also included are novel intermediate compounds.
Abstract: A high yielding extraction process for the purification of N-(2,4-dichloro-5-(4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)methanesulfonamide (sulfentrazone) by selectively partitioning the desired product from the crude mixture, thereby increasing its purity by decreasing the presence of unwanted impurities and improving the color and particle size distribution of the final sulfentrazone product. The selective partitioning is achieved by the sequential use of an organic solvent, water, aqueous inorganic base and a concentrated aqueous inorganic acid.
Type:
Grant
Filed:
October 6, 2020
Date of Patent:
April 25, 2023
Assignee:
Tagros Chemicals India Pvt Ltd
Inventors:
Bomi P Framroze, Rajaiah Shrikrishnan, Rajagopal Kuppuswamy
Abstract: A compound for use in the treatment of a disease ameliorated by the inhibition of Notum of formula (I): (I)
Type:
Grant
Filed:
August 30, 2019
Date of Patent:
April 25, 2023
Assignee:
UCL Business LTD
Inventors:
Paul Vincent Fish, William Mahy, Nicky John Willis, Hannah Woodward, Benjamin N Atkinson, Elliott D Bayle, James Sipthorp, Edith Yvonne Jones, Yuguang Zhao, Luca Vecchia, Reinis Reinholds Ruza
Abstract: A co-drug according to Formula (I) or Formula (II) is provided, R—X—NH—CO—CO—OR1??(I) R—X—CO—O—CH2—CO—OR1??(II) wherein R is a tocol moiety, a tocol analog moiety, or a capsaicinoid moiety; X is a direct bond or a linking group; and OR1 is the residue of an anticancer or antirestenotic agent bearing at least one hydroxyl group by which the CO—OR1 ester linkage is formed. Nanoparticles that include the abovementioned co-drug are also provided, as well as a method of treating a cancer patient that includes administering an effective amount of the co-drug or nanoparticles.
Type:
Grant
Filed:
March 13, 2018
Date of Patent:
April 25, 2023
Assignee:
The Children's Hospital of Philadelphia
Inventors:
Ivan Alferiev, Michael Chorny, Garrett M. Brodeur
Abstract: This invention provides compounds, for example, of Formulae (A)-(H) and (J)-(AA) and pharmaceutically acceptable salts, solvates, esters, amides, and prodrugs thereof. The invention further provides pharmaceutical compositions comprising a compound of the invention, and a pharmaceutically acceptable carrier or vehicle. The compounds and compositions disclosed herein are useful for treating or preventing various diseases and conditions, for example liver disease such as liver fibrosis, fatty liver disease, non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), and kidney diseases such as acute kidney injury (AKI).
Abstract: Described is the use of compositions comprising a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram and a fungicide selected from the group of phosphonates, in particular fosetyl-aluminium for controlling Mosaic scab and reducing Venturia inequalis inoculum in apples, to a method for treating apple plants or apple plant parts for controlling Mosaic scab scab and reducing Venturia inequalis inoculum in apples and to a method for controlling Mosaic scab scab and reducing Venturia inequalis inoculum in plants and plant parts, in particular leaves by treating them with compositions comprising a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram and a fungicide selected from the group of phosphonates, in particular fosetyl-aluminium.
Type:
Grant
Filed:
December 17, 2018
Date of Patent:
April 25, 2023
Assignee:
Bayer Aktiengesellschaft
Inventors:
Sybille Lamprecht, Luk De Maeyer, Gilbert Labourdette
Abstract: The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
Type:
Grant
Filed:
November 24, 2020
Date of Patent:
April 4, 2023
Assignee:
Janssen Pharmaceutica NV
Inventors:
Frances Meredith Hocutt, Barry Eastman Leonard, Jr., Hillary M. Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao